<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Olfactory neuroblastoma (esthesioneuroblastoma)</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Olfactory neuroblastoma (esthesioneuroblastoma)</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Olfactory neuroblastoma (esthesioneuroblastoma)</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Carl Snyderman, MD, MBA</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Robert L Foote, MD, FACR, FASTRO</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Renata Ferrarotto, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Ajit Paintal, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">David M Brizel, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Marvin P Fried, MD, FACS</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Marshall R Posner, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Melinda Yushak, MD, MPH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jul 08, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Olfactory neuroblastoma, also referred to as esthesioneuroblastoma, is a rare malignant tumor of neuroectodermal origin with neuroendocrine differentiation. Olfactory neuroblastomas are thought to arise from the olfactory epithelium [<a href="#rid1">1</a>].</p><p>The clinical presentation, pathology, treatment, and follow-up of patients with olfactory neuroblastomas will be reviewed here. Other malignancies of the nasal cavity and skull base are discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/16861.html" rel="external">"Tumors of the nasal cavity"</a> and  <a class="medical medical_review" href="/z/d/html/3401.html" rel="external">"Paranasal sinus cancer"</a> and  <a class="medical medical_review" href="/z/d/html/5179.html" rel="external">"Chordoma and chondrosarcoma of the skull base"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>Olfactory neuroblastoma makes up approximately two percent of all sinonasal tumors and has an incidence of 0.4 per million population [<a href="#rid2">2</a>]. In patients with olfactory neuroblastomas, the mean age at presentation is 53 years, with most cases occurring in patients between 35 and 70 years of age [<a href="#rid3">3-7</a>]. There is a moderate male predominance with a 59:41 male:female ratio in one series from the Surveillance, Epidemiology, and End Results (SEER) database [<a href="#rid3">3</a>].</p><p class="headingAnchor" id="H3"><span class="h1">CLINICAL MANIFESTATIONS</span><span class="headingEndMark"> — </span>Nasal obstruction due to the presence of a mass is the most common symptom with olfactory neuroblastoma and is present in the majority of cases. Other manifestations of local disease include epistaxis, nasal discharge, and/or pain. When nasal symptoms are present, physical examination usually reveals a red-brown, polypoid mass located high in the nasal cavity.</p><p>Symptoms can also be due to invasion of adjacent structures. Examples of symptoms due to local extension of tumor include:</p><p class="bulletIndent1"><span class="glyph">●</span>Anosmia caused by tumor extension into the cribriform plate</p><p class="bulletIndent1"><span class="glyph">●</span>Pain, proptosis, diplopia, and excessive lacrimation due to orbital extension</p><p class="bulletIndent1"><span class="glyph">●</span>Ear pain and otitis media because of obstruction of the eustachian tube</p><p class="bulletIndent1"><span class="glyph">●</span>Frontal headache due to involvement of the frontal sinus</p><p></p><p>Rarely, patients with olfactory neuroblastomas may have paraneoplastic syndromes due to hormone production, including ectopic adrenocorticotropic hormone syndrome [<a href="#rid4">4,5</a>], hypercalcemia [<a href="#rid6">6</a>], syndrome of inappropriate antidiuretic hormone (SIADH) [<a href="#rid7">7</a>], and hyponatremia [<a href="#rid4">4</a>], as well as neurological paraneoplastic syndromes [<a href="#rid8">8</a>].</p><p class="headingAnchor" id="H1009356873"><span class="h1">DIAGNOSIS AND STAGING</span><span class="headingEndMark"> — </span>The diagnosis of olfactory neuroblastoma requires a tissue biopsy, which is usually obtained during detailed examination of the nasal cavity. Delayed diagnosis is common. (See <a class="local">'Pathology'</a> below.)</p><p class="headingAnchor" id="H1009356920"><span class="h2">Staging</span><span class="headingEndMark"> — </span>There is no uniformly accepted staging system for patients with olfactory neuroblastoma. The Kadish and the Dulguerov systems are most commonly used for staging patients with olfactory neuroblastoma.</p><p class="headingAnchor" id="H1616017951"><span class="h3">Kadish system</span><span class="headingEndMark"> — </span>The most widely used approach is the Kadish clinical staging system  (<a class="graphic graphic_table graphicRef57376" href="/z/d/graphic/57376.html" rel="external">table 1</a>) [<a href="#rid9">9</a>]. As originally proposed, this was a three-tier classification based upon the extent of the primary tumor. This was subsequently modified to include a separate category for patients with lymph node or distant metastases [<a href="#rid10">10</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Stage A – Confined to the nasal cavity</p><p class="bulletIndent1"><span class="glyph">●</span>Stage B – Involvement of one or more paranasal sinuses</p><p class="bulletIndent1"><span class="glyph">●</span>Stage C – Extension beyond the nasal cavity and paranasal sinuses</p><p class="bulletIndent1"><span class="glyph">●</span>Stage D – Regional lymph node or distant metastasis</p><p></p><p>Kadish stage C does not differentiate patients based on the extent of intracranial invasion. However, intracranial invasion with dural involvement has been shown to be a negative prognostic factor for local recurrence and metastasis [<a href="#rid11">11,12</a>].</p><p>Olfactory neuroblastomas are generally slow-growing tumors [<a href="#rid13">13,14</a>]. Patients present most frequently with local (Kadish stage A-C) disease and are less likely to present with regional lymph node or distant metastases (Kadish stage D disease) [<a href="#rid15">15</a>]. As examples, in a National Cancer Database (NCDB) analysis of 1167 patients, 34 percent had Kadish stage A or B disease (disease limited to the nasal cavity or sinuses), 53 percent had stage C disease, and 8 percent had stage D disease [<a href="#rid16">16</a>]. In a review of the Surveillance, Epidemiology, and End Results (SEER) registry, the overall rate of cervical lymph node metastasis was approximately 9 percent [<a href="#rid3">3</a>].</p><p class="headingAnchor" id="H1093743988"><span class="h3">Dulguerov system</span><span class="headingEndMark"> — </span>The Dulguerov system, based upon a modification of the tumor, node, metastasis (TNM) type of classification, may provide superior stratification of patients into prognostic groups  (<a class="graphic graphic_table graphicRef105457" href="/z/d/graphic/105457.html" rel="external">table 2</a>) [<a href="#rid17">17,18</a>]. This was illustrated in a meta-analysis that compared the Kadish and Dulguerov systems using individual level data from 399 patients treated with primary surgery [<a href="#rid18">18</a>]. While higher stage with either system correlated with worse disease-free and overall survival, the Dulguerov system appeared to be a better discriminator of overall survival, especially among patients within the heterogeneous Kadish stage C group. However, not all studies have demonstrated superiority. One study of the NCDB comparing the Kadish, TNM, and modified Dulguerov systems in 883 patients with olfactory neuroblastoma showed no difference in survival outcomes between the three systems [<a href="#rid19">19</a>]. Modifications to the staging system have been proposed to include prognostic factors such as dural infiltration [<a href="#rid20">20</a>].</p><p class="headingAnchor" id="H4"><span class="h2">Imaging studies</span><span class="headingEndMark"> — </span>Computed tomography (CT) and magnetic resonance imaging (MRI) help to differentiate tumor from other causes of nasal obstruction and are essential for tumor staging [<a href="#rid21">21-23</a>]. Origin from the superior nasal cavity medial to the middle turbinate is highly suggestive of olfactory neuroblastoma. Definitive diagnosis requires histologic examination of a biopsy or surgical specimen and may require electron microscopy and immunohistochemistry. (See <a class="local">'Pathology'</a> below.)</p><p class="bulletIndent1">Imaging studies can identify regional nodal or distant metastases at presentation and may include CT, MRI, positron emission tomography (PET), or somatostatin receptor-based imaging (SRI). These imaging modalities may have a role as an adjunct to staging in patients with locally advanced (Kadish C) or high-grade (Hyams grade III or IV) disease, where there is a significant risk of lymphatic metastases or distant disease. (See <a class="local">'Hyams grading system'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>CT </strong>– CT provides the best information about invasion into bony structures and permits detailed assessment of bony erosion or destruction, particularly of the cribriform plate. It can be difficult to differentiate tumor extension versus sinus obstruction with CT alone.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>MRI </strong>– MRI is more accurate for defining the margins of tumor extension into adjacent soft tissue areas, such as the anterior cranial fossa and the orbital tissues. It can also differentiate obstructed secretions from tumor in a sinus that is opacified on CT.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>PET/CT </strong>PET/CT may be helpful in differentiating lymphatic metastases from benign lymphadenopathy when a borderline enlarged lymph node does not meet other criteria for malignancy, such as peripheral enhancement and/or central necrosis. Retropharyngeal lymph nodes are at risk for metastatic disease, but level II lymph nodes are most frequently involved [<a href="#rid24">24</a>]. There are limited data for the role of PET/CT in identifying distant metastases [<a href="#rid25">25</a>]. In one study, PET correctly identified 17 of 20 extracranial metastases, including two distant metastases [<a href="#rid26">26</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>SRI</strong> –<strong> </strong>Most olfactory neuroblastomas express somatostatin receptors, similar to well or moderately differentiated neuroendocrine carcinoma of other origins [<a href="#rid27">27-29</a>]. Observational studies consistently report detection of olfactory neuroblastoma by SRI such as <a class="drug drug_general" data-topicid="16797" href="/z/d/drug information/16797.html" rel="external">indium in-111 pentetreotide</a> (OctreoScan) or <a class="drug drug_general" data-topicid="108440" href="/z/d/drug information/108440.html" rel="external">gallium Ga-68 DOTATATE</a> PET-CT [<a href="#rid27">27,30,31</a>].<strong> </strong>While these imaging modalities have not been formally studied in olfactory neuroblastoma, the use of SRI in conjunction with cross-sectional images is promising and could be offered for initial staging at diagnosis, following definitive therapy with surgery and/or radiation therapy to differentiate tumor and scar tissue, and to select patients for peptide receptor radioligand therapy. (See <a class="local">'Peptide receptor radioligand therapy'</a> below.)</p><p></p><p class="headingAnchor" id="H6"><span class="h1">PATHOLOGY</span></p><p class="headingAnchor" id="H2904242840"><span class="h2">Hyams grading system</span><span class="headingEndMark"> — </span>The Hyams histologic grading system grades tumors from I to IV based upon pathologic features such as mitotic activity and necrosis [<a href="#rid32">32</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>Grade I tumors are characterized by a prominent fibrillary matrix, tumor cells with uniform nuclei, absent mitotic activity, and absent necrosis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Grade II tumors have some fibrillary matrix and exhibit moderate nuclear pleomorphism with some mitotic activity. There is no necrosis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Grade III tumors have a minimal fibrillary matrix and Flexner type rosettes are present. There is more prominent mitotic activity and nuclear pleomorphism, and some necrosis may be seen.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Grade IV tumors have no fibrillary matrix or rosettes and show marked nuclear pleomorphism and increased mitotic activity with frequent necrosis.</p><p></p><p>Hyams grade has been correlated with prognosis. Most data suggest that low-grade lesions (Hyams I and II) are typically associated with better overall survival than high-grade lesions (Hyams III and IV) [<a href="#rid17">17,23,32-35</a>]. </p><p class="headingAnchor" id="H7"><span class="h2">Histopathology</span><span class="headingEndMark"> — </span>On gross examination, biopsy material from olfactory neuroblastoma is soft and hemorrhagic. Resection specimens may show a polypoid appearance. Microscopically, the tumor grows beneath the surface respiratory epithelium and may produce focal ulceration. The vascular supply is rich and fragile, accounting for the hemorrhagic gross appearance. </p><p>In low-grade (Hyams grade I or II) lesions, the tumors display a lobulated growth pattern with nests of tumor cells and intervening septae containing supportive sustentacular cells as well as small blood vessels. Fibrillary stroma comprised of axonal processes is often abundant and is a useful clue to the diagnosis  (<a class="graphic graphic_picture graphicRef50794" href="/z/d/graphic/50794.html" rel="external">picture 1</a>) [<a href="#rid32">32,36</a>]. Cytologically, the tumor cells will contain finely granular cytoplasm. The nuclei are classically round with evenly dispersed, finely speckled chromatin and inconspicuous nucleoli.</p><p>With increasing Hyams grade, the tumors develop a more sheet-like growth pattern with attenuation or loss of the sustentacular cells, greater nuclear pleomorphism, increased mitotic activity, and necrosis.</p><p>Homer-Wright pseudorosettes, which are composed of tumor cells surrounding a core of pink fibrillary material, are seen in one-half of olfactory neuroblastomas; true (Flexner type) rosettes, composed of tumor cells surrounding a central lumen, may be seen in higher-grade tumors. </p><p class="headingAnchor" id="H2677294534"><span class="h2">Molecular findings</span><span class="headingEndMark"> — </span>Comprehensive genetic profiling studies suggest that olfactory neuroblastoma is a genetically heterogeneous entity [<a href="#rid37">37-39</a>]. While high frequency recurrent somatic mutations are uncommon, significant subsets of cases have been found to harbor mutations involving <em>TP53</em>, <em>PIK3CA</em>, <em>NF1</em>, and <em>CDKN2A </em>[<a href="#rid40">40</a>]. <em>FGFR3 </em>and <em>CCND1</em> copy number alterations or amplifications have also been described in a substantial minority of cases [<a href="#rid41">41</a>].</p><p>In a DNA methylation study of 66 cases, four discrete subgroups were identified. The largest group (42 cases) showed low methylation and corresponded to cases with classic, often low-grade, morphology. A second small group (four cases) was found to have increased global methylation without CpG island methylation and also corresponded to classic cases of olfactory neuroblastoma, often low grade. A third group (seven cases) demonstrated increased global as well as CpG island methylation with<em> IDH2</em> point mutations. These tumors were found to have a similar methylation profile as the subset of sinonasal undifferentiated carcinomas (SNUC) harboring<em> IDH2</em> point mutations. Tumors in this group were more likely to be high grade with variant morphology and display aberrant immunohistochemical findings. A fourth group (13 cases) contained tumors with a heterogenous pattern of methylation that was similar to various poorly differentiated tumors (eg, adenocarcinoma, squamous cell carcinoma) within the sinonasal tract. This subset of tumors was often high grade and displayed immunohistochemical evidence of epithelial differentiation [<a href="#rid42">42</a>].</p><p class="headingAnchor" id="H8"><span class="h2">Differential diagnosis</span><span class="headingEndMark"> — </span>While low-grade olfactory neuroblastoma is apparent histologically, high-grade forms often require additional evaluation to refine the differential diagnosis, which includes neuroendocrine carcinoma, SNUC, melanoma, Ewing sarcoma, and metastatic tumors [<a href="#rid43">43</a>]. Misdiagnosis of "small blue cell" tumors occurs frequently and confounds the medical literature. In a series of 12 consecutive patients referred to a cancer center with a histologic diagnosis of olfactory neuroblastoma, 10 patients (83 percent) were misdiagnosed [<a href="#rid44">44</a>]. Distinguishing among these tumors may have therapeutic significance, since the biological behavior and prognosis may differ.</p><p>Immunohistochemistry is an important adjunct in the diagnosis of olfactory neuroblastoma. The tumor cells are typically highlighted by stains for Calretinin [<a href="#rid45">45</a>] as well as neuroendocrine markers (CD56, chromogranin, synaptophysin), while the sustentacular cells are immunoreactive for Sox10 and S100. In typical cases, stains for pancytokeratins (intermediate filaments associated with epithelial differentiation) are negative.</p><p>Tumors most commonly confused with olfactory neuroblastoma include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Sinonasal undifferentiated carcinoma </strong>– SNUC is an aggressive neoplasm that is derived from Schneiderian epithelium. It is composed of medium-sized, polygonal cells with round to oval hyperchromatic nuclei and a scant to moderate amount of eosinophilic cytoplasm. Tumor cells are arranged in nests, wide trabeculae, ribbons, and sheets, with surface dysplasia. Mitoses, necrosis, and vascular invasion are often present [<a href="#rid46">46-48</a>]. SNUC enters into the differential diagnosis of high-grade olfactory neuroblastoma, but in contrast to olfactory neuroblastoma, neurofibrillary stroma and pseudorosettes are typically absent, and the tumor cells will show at least focal evidence of epithelial differentiation by cytokeratin immunochemistry [<a href="#rid47">47</a>]. In cases of Hyams grade IV olfactory neuroblastoma, this distinction may be difficult, particularly in cases with aberrant cytokeratin expression. (See  <a class="medical medical_review" href="/z/d/html/3375.html" rel="external">"Pathology of head and neck neoplasms", section on 'Sinonasal undifferentiated carcinoma'</a>.)</p><p></p><p class="bulletIndent1"><em>IDH2</em> R172 point mutations have been identified in subsets of SNUC as well as high-grade olfactory neuroblastoma, sinonasal adenocarcinoma, and high-grade neuroendocrine carcinoma. Since significant biologic overlap exists between these entities, distinguishing between tumors with this particular genetic alteration may be arbitrary and irreproducible [<a href="#rid49">49</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Large and small cell neuroendocrine carcinoma </strong>– The distinction between high-grade olfactory neuroblastoma and neuroendocrine carcinoma may be difficult as the morphologic overlap may be considerable. Histologically, these are both high-grade lesions. Large cell neuroendocrine carcinoma more typically grows in irregular nests and sheets with peripheral palisading, exhibiting brisk mitotic activity and frequent necrosis. The stroma is desmoplastic and fibrotic, without any fibrillary quality apparent histologically. In small cell neuroendocrine carcinoma, the typical findings of nuclear molding, even chromatin, and high nuclear:cytoplasmic ratios are invariably present.</p><p></p><p class="bulletIndent1">Similar to olfactory neuroblastoma, large and small cell neuroendocrine carcinoma will label immunohistochemically with neuroendocrine markers (CD56, chromogranin, synaptophysin). In contrast to classic cases of olfactory neuroblastoma, immunohistochemical cytokeratin expression is typically seen and no evidence of S100 immunoreactive sustentacular cells is present. </p><p></p><p class="bulletIndent1">Some cases of both olfactory neuroblastoma as well as large cell neuroendocrine carcinoma have been found to harbor <em>IDH2</em> point mutations and may represent different points on the spectrum of a single disease state [<a href="#rid49">49</a>].</p><p></p><p class="bulletIndent1">An additional subset of cases lacking <em>IDH2</em> mutations has been described which exhibits overlapping features of high-grade olfactory neuroblastoma as well as large cell neuroendocrine carcinoma [<a href="#rid50">50</a>]. These cases demonstrate high grade cytology, solid/nested growth, areas of overt neural differentiation, nonfocal pancytokeratin immunoexpression, and the variable presence of S100 immunopositive sustentacular cells. These cases had variably received diagnoses ranging from poorly differentiated carcinoma to high-grade olfactory neuroblastoma. The term "olfactory carcinoma" has been proposed for this pathologically ambiguous subset of cases. While this nomenclature has not yet been widely adopted, this work highlights the diagnostic challenges that exist in this pathologic "gray zone."</p><p></p><p class="headingAnchor" id="H9"><span class="h1">TREATMENT</span><span class="headingEndMark"> — </span>Surgery, radiation therapy (RT), and/or chemotherapy are all used in the treatment of olfactory neuroblastomas [<a href="#rid51">51</a>]. The optimal treatment paradigm has not been established in randomized clinical trials; observational studies generally have limited numbers of patients due to the rarity of this disease. Furthermore, the natural history of the disease necessitates prolonged observation to adequately assess the results of treatment [<a href="#rid52">52</a>]. There are limited data regarding genetic and molecular alterations in olfactory neuroblastoma to guide therapeutic decisions [<a href="#rid40">40,41,53,54</a>].</p><p class="headingAnchor" id="H10"><span class="h2">Primary tumor</span></p><p class="headingAnchor" id="H11"><span class="h3">Surgery</span><span class="headingEndMark"> — </span>Surgery alone for the initial management of patients with an olfactory neuroblastoma is generally restricted to carefully selected patients with early stage (Kadish stage A) and low Hyams grade (I or II) disease because of the poor prognostic discrimination of available staging systems [<a href="#rid19">19</a>], the high risk of local recurrence, and the better results of a combined-modality approach that includes RT. (See <a class="local">'Surgery plus RT'</a> below.)</p><p>Multiple factors may be considered in choosing the optimal surgical approach, including tumor extent, patient comorbidities, reconstruction options, morbidity of surgery, and experience of the surgical team. Morbidities of surgical approaches can differ and should be considered in choosing the best surgical technique. Nonrandomized studies suggest equivalent disease-free survival with different surgical approaches as long as complete excision is achieved [<a href="#rid55">55,56</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Combined craniofacial versus transfacial approach </strong>– Surgical resection of olfactory neuroblastomas originally used a transfacial approach. However, multiple observational studies found that a combined craniofacial approach improved the ability to achieve an en bloc resection and resulted in better local control of disease and improved survival compared with a transfacial approach [<a href="#rid17">17,33,51,57</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Endoscopic versus open surgery – </strong>Advances in surgical techniques have led to the development of a minimally invasive endoscopic approach in carefully selected patients as a way to minimize complications and improve the cosmetic outcome [<a href="#rid55">55,58-66</a>]. Observational data, including meta-analyses and systematic reviews, suggest that endoscopic surgery is also associated with improved overall survival compared with open surgery. However, these data are subject to selection bias, as most patients treated with endoscopic surgery have earlier stage (Kadish stage A/B) disease [<a href="#rid56">56,66,67</a>]. </p><p></p><p class="bulletIndent1">The availability and preference of surgical approach vary between institutions. An endoscopic surgical technique may be combined with a neurosurgical approach for the intracranial component of disease, or with RT.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Extent of surgery </strong>– The extent of surgery may vary depending on tumor stage. Although superior outcomes have generally been observed with craniofacial resection (removal of mucosa, bone of the anterior cranial base, dura, and olfactory bulbs), lesser surgery (extradural resection with preservation of dura and olfactory bulbs) has been proposed for early stage (Kadish A/B) tumors with low Hyams grade as long as resection margins are negative [<a href="#rid68">68</a>]. Although attempts have been made to preserve olfactory function by performing a unilateral resection in patients with unilateral disease, this remains controversial, and there are insufficient data to make any conclusions [<a href="#rid69">69</a>].</p><p></p><p class="headingAnchor" id="H12"><span class="h3">Radiation therapy</span><span class="headingEndMark"> — </span>Radiation therapy (RT) alone has been used for the initial treatment of patients with olfactory neuroblastoma in a number of series, but results have generally been less satisfactory than when RT is used in combination with surgery. RT alone is reserved for patients who are poor surgical candidates, and may include intensity-modulated radiation therapy (IMRT) or proton therapy (IMPT).</p><p>A review of the literature identified 55 cases of olfactory neuroblastoma treated with RT alone [<a href="#rid70">70</a>]. Treatment was successful in preventing disease recurrence in all six cases with Kadish stage A disease at a median follow-up of over eight years. However, for patients with more extensive disease (Kadish stage B and C disease), treatment was successful in only 7 of 12 (58 percent) and 7 of 37 (19 percent) cases, respectively.</p><p>Highly conformal techniques, such as IMRT and IMPT, are now standard to minimize toxicity to adjacent critical structures (retina, optic nerve, optic chiasm, brain stem and brain) [<a href="#rid71">71</a>]. Proton therapy has been utilized to reduce the dose of radiation to critical organs, and to reduce the integral dose to the region and, thus, further reduce toxicity, including radiation-induced malignancies [<a href="#rid72">72-74</a>]. There are no prospective clinical trials comparing outcomes between IMPT and IMRT due to the rarity of olfactory neuroblastoma. </p><p>Proton therapy is also being studied as a way to escalate dose and, thus, improve tumor control, particularly in patients with positive margins or unresectable disease [<a href="#rid75">75</a>]. A systematic review and meta-analysis comparing clinical outcomes with charged particle therapy (carbon ions or protons) and conventional photon RT in patients with malignant tumors of the nasal cavity and paranasal sinuses, including olfactory neuroblastoma, revealed significantly higher disease-free survival at five years (relative risk 1.44, 95% CI 1.01-2.05) and locoregional tumor control at longest follow-up (relative risk 1.26, 95% CI 1.05-1.51) with the use of proton therapy compared with IMRT [<a href="#rid76">76</a>]. However, there was greater neurological toxicity in patients receiving charged particle therapy compared with conventional photon RT.</p><p>Proton therapy may be especially important in children with developing bone, soft tissue, and neurological structures, although olfactory neuroblastomas are extremely rare in this patient population [<a href="#rid75">75</a>]. (See <a class="local">'Pediatric patients'</a> below.)</p><p>Stereotactic radiosurgery has been used to treat recurrent disease. In one report of 31 locally recurrent tumors, 36-month tumor control was 89 percent with stereotactic radiosurgery [<a href="#rid77">77</a>].</p><p>Further details on the use of RT in head and neck cancer are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/3406.html" rel="external">"General principles of radiation therapy for head and neck cancer"</a>.)</p><p class="headingAnchor" id="H13"><span class="h3">Surgery plus RT</span><span class="headingEndMark"> — </span>Observational studies generally indicate that the combination of surgery and radiation therapy (RT) improves disease-free and overall survival compared with either surgery or RT alone [<a href="#rid33">33,78-81</a>]. This combined modality approach is particularly important for patients with disease extending beyond the paranasal sinuses (Kadish stage C  (<a class="graphic graphic_table graphicRef57376" href="/z/d/graphic/57376.html" rel="external">table 1</a>)) or those with positive surgical resection margins. </p><p class="bulletIndent1"><span class="glyph">●</span>For patients treated using combined modality therapy, the choice of surgical approach depends upon the size and extent of the primary tumor. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Kadish stage A and B</strong> – Patients with Kadish stage A and B are typically offered endoscopic endonasal resection of the anterior cranial base. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Kadish stage C</strong> – Patients with stage C disease are typically offered a combined approach of endoscopic and craniofacial resection; however, given data suggest equivalent outcomes as long as complete excision is achieved, the preference for surgical approach (endoscopic versus transcranial/transfacial approaches) varies between institutions and is dependent upon the experience of the surgical team [<a href="#rid55">55</a>].</p><p></p><p class="bulletIndent1">Previously, a combined otolaryngologic and neurosurgical anterior craniofacial resection followed by postoperative RT was the most widely used approach for patients with localized olfactory neuroblastoma [<a href="#rid4">4,33,51,82-85</a>]. (See <a class="local">'Surgery'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For those receiving postoperative RT and no high-risk features (eg, positive surgical margins), we suggest a minimum RT dose of at least 54 Gy in 30 treatments over six weeks [<a href="#rid86">86,87</a>]. </p><p></p><p>Data supporting this approach are as follows:</p><p class="bulletIndent1"><span class="glyph">●</span>This combined modality approach is supported by a literature review and meta-analysis that included 390 patients from 26 studies published between 1990 and 2000 [<a href="#rid33">33</a>]. Among the 169 patients treated with a combination of surgery and RT, the reported five-year survival was 65 percent, whereas the reported five-year survival rates for the 87 patients treated with surgery alone and the 49 patients treated with RT alone were 48 and 37 percent, respectively. Similar added benefit of RT over surgery alone was shown for high-grade tumors in a Surveillance, Epidemiology, and End Results (SEER) study of 281 patients treated from 1973 to 2010 [<a href="#rid80">80</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In an observational series, 70 patients were treated for olfactory neuroblastoma, including 77 percent with T3 or T4 disease and 38 percent with Kadish C or D disease [<a href="#rid88">88</a>]. Ninety percent had surgery as part of therapy, and 66 percent received postoperative RT alone or combined with neoadjuvant or adjuvant chemotherapy. The median follow-up was 7.6 years. Recurrent disease developed in 46 percent, and the median time to recurrence was 6.9 years. Patients with T3 or T4 disease treated with surgery alone had a median disease-specific survival of 88 months, whereas those who were treated with surgery and postoperative RT (with or without concurrent chemotherapy) had a median survival of 219 months.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In an observational series of 30 cases managed predominantly with craniofacial resection and postoperative RT, there were no recurrences in the 11 patients with Kadish A or B disease [<a href="#rid82">82</a>]. Among the 19 cases with Kadish C olfactory neuroblastomas, 9 patients eventually recurred; the 5- and 10-year relapse-free survival rates were 61 and 0 percent, respectively, although the 10-year overall survival rate was 74 percent, emphasizing both the high rate of late relapse in this subset of patients and the ability to salvage both local and regional relapses.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In an observational series of 129 patients with olfactory neuroblastoma treated with open and endoscopic surgery, 59 percent received postoperative radiation therapy (PORT) or concurrent chemoradiation [<a href="#rid81">81</a>]. Five-year overall survival and disease-specific survival were 85.6 and 93.4 percent, respectively. Recurrence rate was 39.6 percent with a median time to recurrence of 42 months. Advanced Kadish stage, orbital invasion, intracranial invasion, and presence of cervical lymphadenopathy at the time of presentation were associated with worsened survival.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In an observational series of 10 patients managed with craniofacial resection and postoperative proton therapy, all 5 patients with negative resection margins remained free of disease [<a href="#rid51">51</a>]. However, four of the five patients with positive margins eventually recurred, including three after a disease-free interval of more than five years.</p><p></p><p class="headingAnchor" id="H14"><span class="h3">Chemotherapy</span><span class="headingEndMark"> — </span>The role of chemotherapy (either before or after RT or surgery; or concurrently with RT) is not established [<a href="#rid89">89</a>]. Although data regarding the benefit of neoadjuvant chemotherapy or concurrent chemoradiation is lacking in adult patients, chemotherapy is often part of the treatment plan for tumors that are unresectable (extensive intracranial/orbital invasion), are advanced stage (Kadish C/D with multiple involved regional lymph nodes) or have a poor prognosis (high grade lesions [Hyams grade 3 or 4]).</p><p>Numerous studies have evaluated various chemotherapy regimens in adult patients in an effort to improve outcomes [<a href="#rid89">89-98</a>]. However, it is unclear whether this actually improves results compared with combined craniofacial resection and RT [<a href="#rid97">97</a>]. However, neoadjuvant chemotherapy is commonly used in pediatric patients. (See <a class="local">'Pediatric patients'</a> below.)</p><p class="headingAnchor" id="H15"><span class="h2">Management of the neck</span></p><p class="headingAnchor" id="H3542068515"><span class="h3">Incidence</span><span class="headingEndMark"> — </span>The cervical lymph nodes are the most frequent site of disseminated disease in patients with olfactory neuroblastoma. The incidence of cervical lymph node metastases at presentation is overall low (&lt;10 percent) [<a href="#rid55">55</a>]. In a review of the SEER registry, the overall rate of cervical lymph node metastasis was approximately 9 percent [<a href="#rid3">3</a>]. In a retrospective review with long-term follow-up, 7 percent of patients presented with primary cervical lymph node metastases, and an additional 9 percent of patients developed delayed cervical lymph node metastases [<a href="#rid99">99</a>], which are frequently associated with relapse or progression at other sites [<a href="#rid100">100,101</a>].</p><p class="headingAnchor" id="H3673274482"><span class="h3">Treatment approach</span><span class="headingEndMark"> — </span>For patients who present with clinical or radiographic evidence of cervical lymph node metastases, treatment is typically surgical resection, with adjuvant RT as clinically indicated using an approach similar to other head and neck cancers. Patients with cervical lymph node metastases at diagnosis are at higher risk for distant metastatic disease and have a significantly worse prognosis than those without cervical lymph node metastases (five-year survival 29 versus 64 percent), providing a rationale for this approach [<a href="#rid3">3,102</a>]. (See  <a class="medical medical_review" href="/z/d/html/3374.html" rel="external">"Adjuvant radiation therapy or chemoradiation in the management of head and neck cancer"</a>.) </p><p>For patients who present without lymph node involvement, the optimal treatment approach is uncertain even for those at high risk for developing disseminated disease. There are no clinical trials that directly compare elective treatment versus observation with salvage therapy for those who do relapse.</p><p class="bulletIndent1"><span class="glyph">●</span>Some experts advocate elective treatment of the neck with RT or selective lymphadenectomy, particularly in those at high risk of developing disseminated disease (Kadish stage C disease or Hyams grade III or IV disease). In one consensus statement based on a systematic review of the literature, for those patients with high-grade tumors and advanced local disease (dural invasion), elective treatment of the N0 neck was suggested to prevent long-term delayed regional lymph node metastases [<a href="#rid55">55</a>]. </p><p></p><p class="bulletIndent1">The rationale for immediate treatment is that this may represent the best opportunity to successfully control disease [<a href="#rid80">80,88,100</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Other experts offer patients observation, with salvage surgery and/or RT if there are isolated, delayed cervical lymph node metastases. This approach is based upon the relatively low risk of developing isolated, delayed cervical lymph node metastases, improved screening with positron emission tomography (PET) scans, the ability to successfully treat many of these patients with salvage therapy (70 percent in the Mayo Clinic series), and the significant toxicity associated with elective cervical lymph node RT [<a href="#rid94">94,101</a>]. </p><p></p><p class="bulletIndent1">Additionally, while elective neck RT can reduce the risk of locoregional nodal disease, it does not necessarily improve survival. While a systematic review and meta-analysis demonstrated a reduced risk of regional recurrence with elective neck RT and observation, it did not show a difference in overall survival [<a href="#rid103">103</a>].</p><p></p><p>In patients with isolated delayed cervical lymph node metastases, multimodality treatment (which includes surgery, RT, and chemotherapy) is of clinical benefit [<a href="#rid101">101,104</a>].</p><p class="headingAnchor" id="H16"><span class="h2">Systemic disease</span><span class="headingEndMark"> — </span>The rarity of olfactory neuroblastomas, combined with the favorable prognosis following aggressive local and regional therapy, has resulted in only very limited experience for patients with disseminated disease. Cytotoxic chemotherapy appears to have activity in some patients, and newer molecularly targeted approaches may become an option as the biology of olfactory neuroblastomas is better understood.</p><p>In a systematic review and meta-analysis of 678 patients, 12 percent developed distant metastatic disease following initial definitive curative treatment of the primary tumor. The median time to the development of distant metastatic disease was 15 months and occurred as late as 276 months. The most common site of distant metastasis was bone (40 percent), followed by drop spinal metastasis (29 percent) and lungs (29 percent). </p><p>The distant metastasis-free survival varied by definitive treatment modality and Kadish stage. The six-month overall survival after the diagnosis of distant metastases was 63 percent. Overall survival was better for patients with drop metastases to the spinal cord, and patients with metastases to visceral organs had the worst overall survival. Patients treated aggressively for distant metastatic disease (using chemotherapy with surgery and/or RT) had a two-year overall survival of 63 percent [<a href="#rid105">105</a>]. </p><p class="headingAnchor" id="H17"><span class="h3">Cytotoxic chemotherapy</span><span class="headingEndMark"> — </span>There are limited data to recommend any specific chemotherapy regimen, given the rarity of this disease; such patients should be enrolled in clinical trials whenever feasible.</p><p>A variety of chemotherapy agents have been evaluated in observational series. These reports have included a mixture of patients with disseminated disease and with locoregional disease where chemotherapy was used alone or in combination with surgery and/or RT [<a href="#rid106">106</a>]. Cisplatin-based combination regimens (particularly <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a> and <a class="drug drug_general" data-topicid="8430" href="/z/d/drug information/8430.html" rel="external">etoposide</a>) have often been chosen, primarily because of their activity in patients with small cell lung cancer or related neuroendocrine-type tumors [<a href="#rid107">107-117</a>]. Non-platinum regimens, such as <a class="drug drug_general" data-topicid="8573" href="/z/d/drug information/8573.html" rel="external">irinotecan</a> plus <a class="drug drug_general" data-topicid="9381" href="/z/d/drug information/9381.html" rel="external">docetaxel</a>, or <a class="drug drug_general" data-topicid="9391" href="/z/d/drug information/9391.html" rel="external">doxorubicin</a>, <a class="drug drug_general" data-topicid="8552" href="/z/d/drug information/8552.html" rel="external">ifosfamide</a>, and <a class="drug drug_general" data-topicid="10045" href="/z/d/drug information/10045.html" rel="external">vincristine</a>, and <a class="drug drug_general" data-topicid="9699" href="/z/d/drug information/9699.html" rel="external">temozolomide</a> may also be active [<a href="#rid116">116-118</a>]. Responses in patients with disseminated disease have generally been of short duration. In patients with distant metastases, the addition of chemotherapy to surgery (with or without RT) was associated with improved overall survival [<a href="#rid105">105</a>].</p><p class="headingAnchor" id="H18"><span class="h3">Targeted therapies</span><span class="headingEndMark"> — </span>An understanding of the molecular pathogenesis of olfactory neuroblastomas may lead to the use of targeted therapies in patients with advanced disease, although these approaches remain investigational.</p><p class="bulletIndent1"><span class="glyph">●</span>In one case report, treatment of a patient with advanced olfactory neuroblastoma using <a class="drug drug_general" data-topicid="10305" href="/z/d/drug information/10305.html" rel="external">sunitinib</a> resulted in stabilization of disease for 15 months after progression following maximal surgery and RT [<a href="#rid119">119</a>]. Immunohistochemistry of a tumor biopsy revealed expression of platelet-derived growth factor.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Signaling in the sonic hedgehog pathway has been associated with tumor cell growth in patients with nevoid basal cell carcinoma and some other tumors. In at least one report, key genes in this pathway were activated in olfactory neuroblastoma cell lines but not in normal olfactory epithelium [<a href="#rid120">120</a>]. If this observation is confirmed, this may offer another target for specific therapy. (See  <a class="medical medical_review" href="/z/d/html/5340.html" rel="external">"Nevoid basal cell carcinoma syndrome (Gorlin syndrome)"</a>.) </p><p></p><p>Several studies have characterized additional mutations and alterations in additional pathways, which may lead to additional treatment options [<a href="#rid40">40,41,54</a>], including <em>FGFR3</em> amplifications and alterations of <em>PIK3CA</em>,<em> NF1</em>,<em> CDKN2A</em>, <em>CDKN2C</em>, and other genes. </p><p>The expression of programmed cell death ligand (PD-L1) by some olfactory neuroblastomas suggests a potential role for immunotherapy with PD-L1 inhibitors to activate tumor-infiltrated CD8+ T cells [<a href="#rid121">121</a>].</p><p class="headingAnchor" id="H2266948512"><span class="h3">Radiation therapy</span><span class="headingEndMark"> — </span>The approach to radiation therapy (RT) for brain and central nervous system, bone, and other visceral metastases in patients with olfactory neuroblastoma is similar to those used for other malignancies [<a href="#rid113">113</a>]. These treatment approaches are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/5212.html" rel="external">"Overview of the treatment of brain metastases"</a> and  <a class="medical medical_review" href="/z/d/html/2820.html" rel="external">"Treatment and prognosis of neoplastic epidural spinal cord compression"</a> and  <a class="medical medical_review" href="/z/d/html/115410.html" rel="external">"Overview of therapeutic approaches for adult patients with bone metastasis from solid tumors", section on 'Radiation therapy'</a> and  <a class="medical medical_review" href="/z/d/html/4617.html" rel="external">"Stereotactic body radiation therapy for lung tumors", section on 'Lung metastases'</a>.)</p><p class="headingAnchor" id="H1154109388"><span class="h3">Peptide receptor radioligand therapy</span><span class="headingEndMark"> — </span>The use of peptide receptor radioligand therapy (PRRT) in patients with metastatic olfactory neuroblastoma remains investigational. Limited case reports suggest that PRRT (which targets the somatostatin receptor) has efficacy in patients with recurrent or metastatic olfactory neuroblastoma, including those with heavily pretreated disease [<a href="#rid20">20,122-125</a>].</p><p>The use of PRRT in other malignancies (eg, neuroendocrine tumors) is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/90664.html" rel="external">"Metastatic well-differentiated pancreatic neuroendocrine tumors: Systemic therapy options to control tumor growth and symptoms of hormone hypersecretion", section on 'Peptide receptor radioligand therapy'</a> and  <a class="medical medical_review" href="/z/d/html/16901.html" rel="external">"Metastatic well-differentiated gastrointestinal neuroendocrine (carcinoid) tumors: Systemic therapy options to control tumor growth", section on 'Somatostatin receptor-expressing tumors'</a>.)</p><p class="headingAnchor" id="H610009459"><span class="h2">Pediatric patients</span><span class="headingEndMark"> — </span>Although olfactory neuroblastoma is more common in adults, it can also occur in children and adolescents. Such patients should be managed at an institution with multidisciplinary experience treating olfactory neuroblastoma. (See <a class="local">'Clinical manifestations'</a> above.)</p><p>For pediatric patients with olfactory neuroblastoma who present with advanced tumors, we suggest induction chemotherapy, administered prior to locoregional therapy (surgery with or without RT), as these patients have high observed response rates to induction chemotherapy and long-term survival with this approach. Data are as follows:</p><p class="bulletIndent1"><span class="glyph">●</span>In an observational study of 24 patients with pediatric olfactory neuroblastoma, neoadjuvant chemotherapy was administered to 13 patients with an 84 percent response rate [<a href="#rid126">126</a>]. A gross total resection was achieved in eight patients with primary surgery and four patients following neoadjuvant chemotherapy. Eighty-eight percent of patients received RT. Five-year disease-free survival of the entire group was 73 percent. Similarly, in another study of 11 children treated with initial chemotherapy followed by surgery and then RT, five-year overall survival was 91 percent [<a href="#rid127">127</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A systematic review of the literature evaluated 94 pediatric patients with olfactory neuroblastoma ranging in age from 0.9 to 21 years [<a href="#rid128">128</a>]. A majority (nearly 90 percent) of patients had advanced disease (stage Kadish B or C tumors at presentation) and 20 percent presented with cervical lymphadenopathy. Approximately 50 of patients were treated with multimodality therapy (chemotherapy, surgery, and RT). At median follow-up of 3 to 13 years, the five-year overall survival for the entire study population ranged from 44 to 91 percent.</p><p></p><p>The use of RT in pediatric patients can induce late toxicities, particularly near sensitive neurological and bony structures that may not have reached full development. As an example, one study of eight patients treated with proton therapy demonstrated a four-year overall survival rate of 88 percent [<a href="#rid75">75</a>]. However, four patients had late radiation-related toxicities, including endocrine dysfunction, retinopathy, and optic neuropathy due to dose escalation.</p><p class="headingAnchor" id="H734806838"><span class="h2">Prognosis</span><span class="headingEndMark"> — </span>The prognosis for patients with olfactory neuroblastoma is influenced both by the extent of disease and the pathologic grade. Patient age may also be a prognostic factor independent of tumor stage or treatment [<a href="#rid129">129,130</a>].</p><p>In a National Cancer Database (NCDB) analysis of 1167 patients, 34 percent of patients had Kadish stage A or B disease, while 53 percent had stage C and 8 percent had stage D disease [<a href="#rid16">16</a>]. The five-year overall survival rate for the entire series was 77 percent; for patients with Kadish stages A, B, C, and D, the five-year survival rates were 80, 88, 77, and 50 percent, respectively. Although there was a slight bias in terms of treating Kadish stage B patients, as 15 percent more received RT than stage A patients, this was not enough to account for the difference in survival between these two groups. One study of the NCDB comparing the Kadish; tumor, node, metastasis (TNM); and modified Dulguerov systems showed no difference in survival prediction with the three systems [<a href="#rid19">19</a>].</p><p>Data suggest a poorer prognosis in those with higher Hyams grade tumors [<a href="#rid33">33,77,80,130-132</a>]. A meta-analysis of the published literature from 1983 to 2018 looked at Hyams grade as a predictor of metastasis and overall survival [<a href="#rid131">131</a>]. The analysis included 525 patients for tumor metastases and 563 patients for overall survival. Neck metastasis was observed in 18 percent of high-grade Hyams and 8 percent of low-grade Hyams patients. Distant metastasis was noted in 21 percent of high-grade Hyams versus 9 percent of low-grade Hyams patients. Low-grade Hyams patients had 5- and 10-year overall survival rates of 81 and 64 percent, respectively, as compared with 61 and 41 percent, respectively, for high-grade Hyams patients. Taken as a whole, these data may imply that Hyams grade, when available, is more prognostic that Kadish stage, although Kadish stage may have prognostic relevance in high-grade Hyams tumors.</p><p class="headingAnchor" id="H19"><span class="h1">POSTTREATMENT SURVEILLANCE</span><span class="headingEndMark"> — </span>There are no formal guidelines for appropriate follow-up after treatment for olfactory neuroblastoma. Extended clinical and imaging follow-up is indicated [<a href="#rid4">4,51,82,83,133</a>]. Approximately 10 to 20 percent of patients may experience local or regional recurrence for at least 10 years after initial therapy [<a href="#rid133">133</a>], and treatment of recurrences is associated with prolonged disease-free survival. </p><p>For posttreatment surveillance, we offer baseline magnetic resonance imaging (MRI) of the brain with attention to the face (for maxillofacial imaging of the nasal cavity and paranasal sinuses) and skull base at two to three months after treatment completion. MRI is then repeated at six-month intervals for approximately two years, followed by yearly examinations until five years after completing treatment. Positron emission tomography/computed tomography (PET/CT) and/or somatostatin receptor-based imaging (SRI) with either <a class="drug drug_general" data-topicid="16797" href="/z/d/drug information/16797.html" rel="external">indium In-111 pentetreotide</a> (OctreoScan) or <a class="drug drug_general" data-topicid="108440" href="/z/d/drug information/108440.html" rel="external">gallium Ga-68 DOTATATE</a> PET-CT may also be offered for detection of occult regional and distant metastases and for evaluation of marginally enlarged cervical lymph nodes. Clinical follow-up should continue beyond five years, with consideration of additional imaging at one- to two-year intervals in high-risk patients.</p><p class="headingAnchor" id="H926080384"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/128559.html" rel="external">"Society guideline links: Head and neck cancer"</a>.)</p><p class="headingAnchor" id="H20"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical manifestations</strong> – Olfactory neuroblastoma, also known as esthesioneuroblastoma, is a neuroectodermal malignancy of the nasal cavity, which usually presents with locally invasive disease. Olfactory neuroblastomas have a marked tendency for late local and regional recurrences. (See <a class="local">'Clinical manifestations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment </strong>– For patients with locoregional disease, surgery has a primary role in the management of these patients, and the best results are associated with a combination of surgery and radiation therapy (RT). There are limited data for chemotherapy as part of planned multimodality therapy for initial treatment. (See <a class="local">'Chemotherapy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For select patients with Kadish stage A  (<a class="graphic graphic_table graphicRef57376" href="/z/d/graphic/57376.html" rel="external">table 1</a>) and low Hyams grade (I or II) tumor, we suggest surgical excision rather than surgery plus RT (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). Endoscopic endonasal surgery is preferred for such early-stage tumors, with surgery limited to an extradural resection in selected cases. (See <a class="local">'Surgery'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with Kadish B and C primary tumors or advanced Hyams grade (III or IV), we suggest a combination of surgery and RT (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Surgery plus RT'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Patients with Kadish stage B tumors, are typically treated with endoscopic endonasal surgery due to less morbidity and equivalent oncologic outcomes. </p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Patients with Kadish stage C tumors are typically treated using a combined approach of endoscopic and craniofacial resection. However, preference for surgical technique varies between institutions and is dependent on the experience of the surgical team.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>RT alone is reserved for patients who are poor surgical candidates, and it may include intensity-modulated radiation therapy (IMRT) or proton therapy (IMPT). (See <a class="local">'Radiation therapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pediatric patients</strong> – For pediatric patients with olfactory neuroblastoma who present with advanced tumors, we suggest induction chemotherapy (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>), administered prior to locoregional therapy (surgery with or without RT), as these patients have high observed response rates to induction chemotherapy and long-term survival with this approach. (See <a class="local">'Pediatric patients'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Posttreatment surveillance</strong> – Patients with olfactory neuroblastoma may develop recurrences 10 or more years following initial treatment. Thus, prolonged surveillance for evidence of local or regional recurrence is indicated. (See <a class="local">'Posttreatment surveillance'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Locoregionally recurrent disease</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Aggressive local therapy with surgery and/or RT is indicated for patients with local recurrence without distant metastases, since a significant number of such patients may have prolonged disease-free survival.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Surgery with or without RT is indicated for patients with isolated delayed cervical lymph node metastases. Aggressive therapy in this setting can result in prolonged disease-free survival in some patients. (See <a class="local">'Management of the neck'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Advanced and metastatic disease</strong> – Systemic treatment may provide clinically useful palliation of patients with advanced olfactory neuroblastoma who are not candidates for definitive surgery or RT. There are limited data to recommend any specific chemotherapy regimen; such patients should be enrolled in clinical protocols whenever feasible. (See <a class="local">'Cytotoxic chemotherapy'</a> above.)</p><p></p><p class="headingAnchor" id="H256719993"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Derrick Lin, MD, Bruce E Brockstein, MD, and Jerome B Taxy, MD, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">Neuroectodermal tumours. In: Pathology and Genetics of Head and Neck Tumours, Barnes L, Eveson JW, Reichart P, Sidransky D (Eds), IARC Press, Lyon, France 2005.</li><li><a class="nounderline abstract_t">Thompson LD. Olfactory neuroblastoma. Head Neck Pathol 2009; 3:252.</a></li><li><a class="nounderline abstract_t">Kuan EC, Nasser HB, Carey RM, et al. A Population-Based Analysis of Nodal Metastases in Esthesioneuroblastomas of the Sinonasal Tract. Laryngoscope 2019; 129:1025.</a></li><li><a class="nounderline abstract_t">Ward PD, Heth JA, Thompson BG, Marentette LJ. Esthesioneuroblastoma: Results and Outcomes of a Single Institution's Experience. Skull Base 2009; 19:133.</a></li><li><a class="nounderline abstract_t">Koo BK, An JH, Jeon KH, et al. Two cases of ectopic adrenocorticotropic hormone syndrome with olfactory neuroblastoma and literature review. Endocr J 2008; 55:469.</a></li><li><a class="nounderline abstract_t">Sharma S, Lasheen W, Walsh D. Paraneoplastic refractory hypercalcemia due to advanced metastatic esthesioneuroblastoma. Rhinology 2008; 46:153.</a></li><li><a class="nounderline abstract_t">Gabbay U, Leider-Trejo L, Marshak G, et al. A case and a series of published cases of esthesioneuroblastoma (ENB) in which long-standing paraneoplastic SIADH had preceded ENB diagnosis. Ear Nose Throat J 2013; 92:E6.</a></li><li><a class="nounderline abstract_t">Kunc M, Gabrych A, Czapiewski P, Sworczak K. Paraneoplastic syndromes in olfactory neuroblastoma. Contemp Oncol (Pozn) 2015; 19:6.</a></li><li><a class="nounderline abstract_t">Kadish S, Goodman M, Wang CC. Olfactory neuroblastoma. A clinical analysis of 17 cases. Cancer 1976; 37:1571.</a></li><li><a class="nounderline abstract_t">Morita A, Ebersold MJ, Olsen KD, et al. Esthesioneuroblastoma: prognosis and management. Neurosurgery 1993; 32:706.</a></li><li><a class="nounderline abstract_t">Yu Y, El-Sayed IH, McDermott MW, et al. Dural recurrence among esthesioneuroblastoma patients presenting with intracranial extension. Laryngoscope 2018; 128:2226.</a></li><li><a class="nounderline abstract_t">Marinelli JP, Janus JR, Van Gompel JJ, et al. Dural Invasion Predicts the Laterality and Development of Neck Metastases in Esthesioneuroblastoma. J Neurol Surg B Skull Base 2018; 79:495.</a></li><li><a class="nounderline abstract_t">Jethanamest D, Morris LG, Sikora AG, Kutler DI. Esthesioneuroblastoma: a population-based analysis of survival and prognostic factors. Arch Otolaryngol Head Neck Surg 2007; 133:276.</a></li><li><a class="nounderline abstract_t">Broich G, Pagliari A, Ottaviani F. Esthesioneuroblastoma: a general review of the cases published since the discovery of the tumour in 1924. Anticancer Res 1997; 17:2683.</a></li><li><a class="nounderline abstract_t">Dumont B, Fresneau B, Claude L, et al. Pattern of loco-regional relapses and treatment in pediatric esthesioneuroblastoma: The French very rare tumors group (Fracture) contribution. Pediatr Blood Cancer 2020; 67:e28154.</a></li><li><a class="nounderline abstract_t">Konuthula N, Iloreta AM, Miles B, et al. Prognostic significance of Kadish staging in esthesioneuroblastoma: An analysis of the National Cancer Database. Head Neck 2017; 39:1962.</a></li><li><a class="nounderline abstract_t">Dulguerov P, Calcaterra T. Esthesioneuroblastoma: the UCLA experience 1970-1990. Laryngoscope 1992; 102:843.</a></li><li><a class="nounderline abstract_t">Arnold MA, Farnoosh S, Gore MR. Comparing Kadish and Modified Dulguerov Staging Systems for Olfactory Neuroblastoma: An Individual Participant Data Meta-analysis. Otolaryngol Head Neck Surg 2020; 163:418.</a></li><li><a class="nounderline abstract_t">Joshi RR, Husain Q, Roman BR, et al. Comparing Kadish, TNM, and the modified Dulguerov staging systems for esthesioneuroblastoma. J Surg Oncol 2019; 119:130.</a></li><li><a class="nounderline abstract_t">Lechner M, Takahashi Y, Turri-Zanoni M, et al. Clinical outcomes, Kadish-INSICA staging and therapeutic targeting of somatostatin receptor 2 in olfactory neuroblastoma. Eur J Cancer 2022; 162:221.</a></li><li><a class="nounderline abstract_t">Pickuth D, Heywang-Köbrunner SH, Spielmann RP. Computed tomography and magnetic resonance imaging features of olfactory neuroblastoma: an analysis of 22 cases. Clin Otolaryngol Allied Sci 1999; 24:457.</a></li><li><a class="nounderline abstract_t">Derdeyn CP, Moran CJ, Wippold FJ 2nd, et al. MRI of esthesioneuroblastoma. J Comput Assist Tomogr 1994; 18:16.</a></li><li><a class="nounderline abstract_t">Kairemo KJ, Jekunen AP, Kestilä MS, Ramsay HA. Imaging of olfactory neuroblastoma--an analysis of 17 cases. Auris Nasus Larynx 1998; 25:173.</a></li><li><a class="nounderline abstract_t">Howell MC, Branstetter BF 4th, Snyderman CH. Patterns of regional spread for esthesioneuroblastoma. AJNR Am J Neuroradiol 2011; 32:929.</a></li><li><a class="nounderline abstract_t">Broski SM, Hunt CH, Johnson GB, et al. The added value of 18F-FDG PET/CT for evaluation of patients with esthesioneuroblastoma. J Nucl Med 2012; 53:1200.</a></li><li><a class="nounderline abstract_t">Fujioka T, Toriihara A, Kubota K, et al. Long-term follow-up using 18F-FDG PET/CT for postoperative olfactory neuroblastoma. Nucl Med Commun 2014; 35:857.</a></li><li><a class="nounderline abstract_t">Rostomily RC, Elias M, Deng M, et al. Clinical utility of somatostatin receptor scintigraphic imaging (octreoscan) in esthesioneuroblastoma: a case study and survey of somatostatin receptor subtype expression. Head Neck 2006; 28:305.</a></li><li><a class="nounderline abstract_t">Czapiewski P, Kunc M, Gorczyński A, et al. Frequent expression of somatostatin receptor 2a in olfactory neuroblastomas: a new and distinctive feature. Hum Pathol 2018; 79:144.</a></li><li><a class="nounderline abstract_t">Cracolici V, Wang EW, Gardner PA, et al. SSTR2 Expression in Olfactory Neuroblastoma: Clinical and Therapeutic Implications. Head Neck Pathol 2021; 15:1185.</a></li><li><a class="nounderline abstract_t">Gains JE, Aldridge MD, Mattoli MV, et al. 68Ga-DOTATATE and 123I-mIBG as imaging biomarkers of disease localisation in metastatic neuroblastoma: implications for molecular radiotherapy. Nucl Med Commun 2020; 41:1169.</a></li><li><a class="nounderline abstract_t">Liu KY, Goldrich DY, Ninan SJ, et al. The value of 68 Gallium-DOTATATE PET/CT in sinonasal neuroendocrine tumor management: A case series. Head Neck 2021; 43:E30.</a></li><li class="breakAll">Hyams VJ, Batsakis JG, Michaels L. Tumors of the upper respiratory tract and ear. In: Atlas of Tumor Pathology, Armed Forces Institute of Pathology, 1988.</li><li><a class="nounderline abstract_t">Dulguerov P, Allal AS, Calcaterra TC. Esthesioneuroblastoma: a meta-analysis and review. Lancet Oncol 2001; 2:683.</a></li><li><a class="nounderline abstract_t">Vuong HG, Ngo TNM, Dunn IF. Consolidating the Hyams grading system in esthesioneuroblastoma - an individual participant data meta-analysis. J Neurooncol 2021; 153:15.</a></li><li><a class="nounderline abstract_t">Tajudeen BA, Arshi A, Suh JD, et al. Esthesioneuroblastoma: an update on the UCLA experience, 2002-2013. J Neurol Surg B Skull Base 2015; 76:43.</a></li><li><a class="nounderline abstract_t">Hirose T, Scheithauer BW, Lopes MB, et al. Olfactory neuroblastoma. An immunohistochemical, ultrastructural, and flow cytometric study. Cancer 1995; 76:4.</a></li><li><a class="nounderline abstract_t">Kaur RP, Izumchenko E, Blakaj DM, et al. The genomics and epigenetics of olfactory neuroblastoma: A systematic review. Laryngoscope Investig Otolaryngol 2021; 6:721.</a></li><li><a class="nounderline abstract_t">Friedman J, Schumacher JK, Papagiannopoulos P, et al. Targeted 595-gene genomic profiling demonstrates low tumor mutational burden in olfactory neuroblastoma. Int Forum Allergy Rhinol 2021; 11:58.</a></li><li><a class="nounderline abstract_t">Romani C, Bignotti E, Mattavelli D, et al. Gene Expression Profiling of Olfactory Neuroblastoma Helps Identify Prognostic Pathways and Define Potentially Therapeutic Targets. Cancers (Basel) 2021; 13.</a></li><li><a class="nounderline abstract_t">Gay LM, Kim S, Fedorchak K, et al. Comprehensive Genomic Profiling of Esthesioneuroblastoma Reveals Additional Treatment Options. Oncologist 2017; 22:834.</a></li><li><a class="nounderline abstract_t">Lazo de la Vega L, McHugh JB, Cani AK, et al. Comprehensive Molecular Profiling of Olfactory Neuroblastoma Identifies Potentially Targetable FGFR3 Amplifications. Mol Cancer Res 2017; 15:1551.</a></li><li><a class="nounderline abstract_t">Capper D, Engel NW, Stichel D, et al. DNA methylation-based reclassification of olfactory neuroblastoma. Acta Neuropathol 2018; 136:255.</a></li><li><a class="nounderline abstract_t">Bell D. Sinonasal Neuroendocrine Neoplasms: Current Challenges and Advances in Diagnosis and Treatment, with a Focus on Olfactory Neuroblastoma. Head Neck Pathol 2018; 12:22.</a></li><li><a class="nounderline abstract_t">Cohen ZR, Marmor E, Fuller GN, DeMonte F. Misdiagnosis of olfactory neuroblastoma. Neurosurg Focus 2002; 12:e3.</a></li><li><a class="nounderline abstract_t">Wooff JC, Weinreb I, Perez-Ordonez B, et al. Calretinin staining facilitates differentiation of olfactory neuroblastoma from other small round blue cell tumors in the sinonasal tract. Am J Surg Pathol 2011; 35:1786.</a></li><li class="breakAll">Barnes L, Peel RL. Olfactory neuroblastomas versus sinonasal undifferentiated carcinoma. In: Head and Neck Pathology. A Text/Atlas of Differential Diagnosis, Igaku-Shoin, New York 1990. p.152.</li><li><a class="nounderline abstract_t">Frierson HF Jr, Mills SE, Fechner RE, et al. Sinonasal undifferentiated carcinoma. An aggressive neoplasm derived from schneiderian epithelium and distinct from olfactory neuroblastoma. Am J Surg Pathol 1986; 10:771.</a></li><li><a class="nounderline abstract_t">Mills SE, Fechner RE. "Undifferentiated" neoplasms of the sinonasal region: differential diagnosis based on clinical, light microscopic, immunohistochemical, and ultrastructural features. Semin Diagn Pathol 1989; 6:316.</a></li><li><a class="nounderline abstract_t">Dogan S, Vasudevaraja V, Xu B, et al. DNA methylation-based classification of sinonasal undifferentiated carcinoma. Mod Pathol 2019; 32:1447.</a></li><li><a class="nounderline abstract_t">Rooper LM, Bishop JA, Faquin WC, et al. Sinonasal Tumors With Neuroepithelial Differentiation (Olfactory Carcinoma): Delineation of Their Pathologic and Clinical Features With Insights into Their Relationship to Olfactory Neuroblastoma and Sinonasal Carcinoma. Am J Surg Pathol 2022; 46:1025.</a></li><li><a class="nounderline abstract_t">Nichols AC, Chan AW, Curry WT, et al. Esthesioneuroblastoma: the massachusetts eye and ear infirmary and massachusetts general hospital experience with craniofacial resection, proton beam radiation, and chemotherapy. Skull Base 2008; 18:327.</a></li><li><a class="nounderline abstract_t">Simon JH, Zhen W, McCulloch TM, et al. Esthesioneuroblastoma: the University of Iowa experience 1978-1998. Laryngoscope 2001; 111:488.</a></li><li><a class="nounderline abstract_t">Czapiewski P, Kunc M, Haybaeck J. Genetic and molecular alterations in olfactory neuroblastoma: implications for pathogenesis, prognosis and treatment. Oncotarget 2016; 7:52584.</a></li><li><a class="nounderline abstract_t">Topcagic J, Feldman R, Ghazalpour A, et al. Comprehensive molecular profiling of advanced/metastatic olfactory neuroblastomas. PLoS One 2018; 13:e0191244.</a></li><li><a class="nounderline abstract_t">Wang EW, Zanation AM, Gardner PA, et al. ICAR: endoscopic skull-base surgery. Int Forum Allergy Rhinol 2019; 9:S145.</a></li><li><a class="nounderline abstract_t">Fu TS, Monteiro E, Muhanna N, et al. Comparison of outcomes for open versus endoscopic approaches for olfactory neuroblastoma: A systematic review and individual participant data meta-analysis. Head Neck 2016; 38 Suppl 1:E2306.</a></li><li><a class="nounderline abstract_t">Levine PA, McLean WC, Cantrell RW. Esthesioneuroblastoma: the University of Virginia experience 1960-1985. Laryngoscope 1986; 96:742.</a></li><li><a class="nounderline abstract_t">Unger F, Haselsberger K, Walch C, et al. Combined endoscopic surgery and radiosurgery as treatment modality for olfactory neuroblastoma (esthesioneuroblastoma). Acta Neurochir (Wien) 2005; 147:595.</a></li><li><a class="nounderline abstract_t">Folbe A, Herzallah I, Duvvuri U, et al. Endoscopic endonasal resection of esthesioneuroblastoma: a multicenter study. Am J Rhinol Allergy 2009; 23:91.</a></li><li><a class="nounderline abstract_t">Kim BJ, Kim DW, Kim SW, et al. Endoscopic versus traditional craniofacial resection for patients with sinonasal tumors involving the anterior skull base. Clin Exp Otorhinolaryngol 2008; 1:148.</a></li><li><a class="nounderline abstract_t">Nicolai P, Battaglia P, Bignami M, et al. Endoscopic surgery for malignant tumors of the sinonasal tract and adjacent skull base: a 10-year experience. Am J Rhinol 2008; 22:308.</a></li><li><a class="nounderline abstract_t">Gallia GL, Asemota AO, Blitz AM, et al. Endonasal endoscopic resection of olfactory neuroblastoma: an 11-year experience. J Neurosurg 2018; 131:238.</a></li><li><a class="nounderline abstract_t">de Gabory L, Verillaud B, Rumeau C, et al. Multicenter assessment of exclusive endoscopic endonasal approach for the treatment of 53 olfactory neuroblastomas. Head Neck 2018; 40:1000.</a></li><li><a class="nounderline abstract_t">Nakagawa T, Kodama S, Kobayashi M, et al. Endoscopic endonasal management of esthesioneuroblastoma: A retrospective multicenter study. Auris Nasus Larynx 2018; 45:281.</a></li><li><a class="nounderline abstract_t">Spielman DB, Liebowitz A, Grewal M, et al. Exclusively endoscopic surgical resection of esthesioneuroblastoma: A systematic review. World J Otorhinolaryngol Head Neck Surg 2022; 8:66.</a></li><li><a class="nounderline abstract_t">Barinsky GL, Azmy MC, Kilic S, et al. Comparison of Open and Endoscopic Approaches in the Resection of Esthesioneuroblastoma. Ann Otol Rhinol Laryngol 2021; 130:136.</a></li><li><a class="nounderline abstract_t">Devaiah AK, Andreoli MT. Treatment of esthesioneuroblastoma: a 16-year meta-analysis of 361 patients. Laryngoscope 2009; 119:1412.</a></li><li><a class="nounderline abstract_t">Mays AC, Bell D, Ferrarotto R, et al. Early Stage olfactory neuroblastoma and the impact of resecting dura and olfactory bulb. Laryngoscope 2018; 128:1274.</a></li><li><a class="nounderline abstract_t">Gompel JJV, Janus JR, Hughes JD, et al. Esthesioneuroblastoma and Olfactory Preservation: Is it Reasonable to Attempt Smell Preservation? J Neurol Surg B Skull Base 2018; 79:184.</a></li><li><a class="nounderline abstract_t">Benfari G, Fusconi M, Ciofalo A, et al. Radiotherapy alone for local tumour control in esthesioneuroblastoma. Acta Otorhinolaryngol Ital 2008; 28:292.</a></li><li><a class="nounderline abstract_t">Madani I, Bonte K, Vakaet L, et al. Intensity-modulated radiotherapy for sinonasal tumors: Ghent University Hospital update. Int J Radiat Oncol Biol Phys 2009; 73:424.</a></li><li><a class="nounderline abstract_t">Dagan R, Bryant C, Li Z, et al. Outcomes of Sinonasal Cancer Treated With Proton Therapy. Int J Radiat Oncol Biol Phys 2016; 95:377.</a></li><li><a class="nounderline abstract_t">Nakamura N, Zenda S, Tahara M, et al. Proton beam therapy for olfactory neuroblastoma. Radiother Oncol 2017; 122:368.</a></li><li class="breakAll">National Comprehensive Cancer Network (NCCN) guidelines. Available at: https://www.nccn.org/professionals/physician_gls/f_guidelines.asp#site (Accessed on May 08, 2017).</li><li><a class="nounderline abstract_t">Lucas JT Jr, Ladra MM, MacDonald SM, et al. Proton therapy for pediatric and adolescent esthesioneuroblastoma. Pediatr Blood Cancer 2015; 62:1523.</a></li><li><a class="nounderline abstract_t">Patel SH, Wang Z, Wong WW, et al. Charged particle therapy versus photon therapy for paranasal sinus and nasal cavity malignant diseases: a systematic review and meta-analysis. Lancet Oncol 2014; 15:1027.</a></li><li><a class="nounderline abstract_t">Van Gompel JJ, Giannini C, Olsen KD, et al. Long-term outcome of esthesioneuroblastoma: hyams grade predicts patient survival. J Neurol Surg B Skull Base 2012; 73:331.</a></li><li><a class="nounderline abstract_t">Fiani B, Quadri SA, Cathel A, et al. Esthesioneuroblastoma: A Comprehensive Review of Diagnosis, Management, and Current Treatment Options. World Neurosurg 2019; 126:194.</a></li><li><a class="nounderline abstract_t">Alotaibi HA, Priola SM, Bernat AL, Farrash F. Esthesioneuroblastoma: Summary of Single-center Experiences with Focus on Adjuvant Therapy and Overall Survival. Cureus 2019; 11:e4897.</a></li><li><a class="nounderline abstract_t">Tajudeen BA, Arshi A, Suh JD, et al. Importance of tumor grade in esthesioneuroblastoma survival: a population-based analysis. JAMA Otolaryngol Head Neck Surg 2014; 140:1124.</a></li><li><a class="nounderline abstract_t">Abdelmeguid AS, Bell D, Roberts D, et al. Long-Term Outcomes of Olfactory Neuroblastoma: MD Anderson Cancer Center Experience and Review of the Literature. Laryngoscope 2022; 132:290.</a></li><li><a class="nounderline abstract_t">Diaz EM Jr, Johnigan RH 3rd, Pero C, et al. Olfactory neuroblastoma: the 22-year experience at one comprehensive cancer center. Head Neck 2005; 27:138.</a></li><li><a class="nounderline abstract_t">Bachar G, Goldstein DP, Shah M, et al. Esthesioneuroblastoma: The Princess Margaret Hospital experience. Head Neck 2008; 30:1607.</a></li><li><a class="nounderline abstract_t">Lund VJ, Howard D, Wei W, Spittle M. Olfactory neuroblastoma: past, present, and future? Laryngoscope 2003; 113:502.</a></li><li><a class="nounderline abstract_t">Theilgaard SA, Buchwald C, Ingeholm P, et al. Esthesioneuroblastoma: a Danish demographic study of 40 patients registered between 1978 and 2000. Acta Otolaryngol 2003; 123:433.</a></li><li><a class="nounderline abstract_t">Foote RL, Morita A, Ebersold MJ, et al. Esthesioneuroblastoma: the role of adjuvant radiation therapy. Int J Radiat Oncol Biol Phys 1993; 27:835.</a></li><li><a class="nounderline abstract_t">Ozsahin M, Gruber G, Olszyk O, et al. Outcome and prognostic factors in olfactory neuroblastoma: a rare cancer network study. Int J Radiat Oncol Biol Phys 2010; 78:992.</a></li><li><a class="nounderline abstract_t">Ow TJ, Hanna EY, Roberts DB, et al. Optimization of long-term outcomes for patients with esthesioneuroblastoma. Head Neck 2014; 36:524.</a></li><li><a class="nounderline abstract_t">Cranmer LD, Chau B, Rockhill JK, et al. Chemotherapy in Esthesioneuroblastoma/Olfactory Neuroblastoma: An Analysis of the Surveillance Epidemiology and End Results (SEER) 1973-2015 Database. Am J Clin Oncol 2020; 43:203.</a></li><li><a class="nounderline abstract_t">Fitzek MM, Thornton AF, Varvares M, et al. Neuroendocrine tumors of the sinonasal tract. Results of a prospective study incorporating chemotherapy, surgery, and combined proton-photon radiotherapy. Cancer 2002; 94:2623.</a></li><li><a class="nounderline abstract_t">Eich HT, Hero B, Staar S, et al. Multimodality therapy including radiotherapy and chemotherapy improves event-free survival in stage C esthesioneuroblastoma. Strahlenther Onkol 2003; 179:233.</a></li><li><a class="nounderline abstract_t">Zappia JJ, Carroll WR, Wolf GT, et al. Olfactory neuroblastoma: the results of modern treatment approaches at the University of Michigan. Head Neck 1993; 15:190.</a></li><li><a class="nounderline abstract_t">Loy AH, Reibel JF, Read PW, et al. Esthesioneuroblastoma: continued follow-up of a single institution's experience. Arch Otolaryngol Head Neck Surg 2006; 132:134.</a></li><li><a class="nounderline abstract_t">Argiris A, Dutra J, Tseke P, Haines K. Esthesioneuroblastoma: the Northwestern University experience. Laryngoscope 2003; 113:155.</a></li><li><a class="nounderline abstract_t">Bartel R, Gonzalez-Compta X, Cisa E, et al. Importance of neoadjuvant chemotherapy in olfactory neuroblastoma treatment: Series report and literature review. Acta Otorrinolaringol Esp (Engl Ed) 2018; 69:208.</a></li><li><a class="nounderline abstract_t">Su SY, Bell D, Ferrarotto R, et al. Outcomes for olfactory neuroblastoma treated with induction chemotherapy. Head Neck 2017; 39:1671.</a></li><li><a class="nounderline abstract_t">Miller KC, Marinelli JP, Van Gompel JJ, et al. Utility of adjuvant chemotherapy in patients receiving surgery and adjuvant radiotherapy for primary treatment of esthesioneuroblastoma. Head Neck 2019; 41:1335.</a></li><li><a class="nounderline abstract_t">Resteghini C, Castelnuovo P, Nicolai P, et al. The SINTART 1 study. A phase II non-randomised controlled trial of induction chemotherapy, surgery, photon-, proton- and carbon ion-based radiotherapy integration in patients with locally advanced resectable sinonasal tumours. Eur J Cancer 2023; 187:185.</a></li><li><a class="nounderline abstract_t">Nalavenkata SB, Sacks R, Adappa ND, et al. Olfactory Neuroblastoma: Fate of the Neck--A Long-term Multicenter Retrospective Study. Otolaryngol Head Neck Surg 2016; 154:383.</a></li><li><a class="nounderline abstract_t">Demiroz C, Gutfeld O, Aboziada M, et al. Esthesioneuroblastoma: is there a need for elective neck treatment? Int J Radiat Oncol Biol Phys 2011; 81:e255.</a></li><li><a class="nounderline abstract_t">Peacock JG, Harmsen WS, Link MJ, et al. Risk of Delayed Lymph Node Metastasis in Clinically N0 Esthesioneuroblastoma. J Neurol Surg B Skull Base 2017; 78:68.</a></li><li><a class="nounderline abstract_t">Banuchi VE, Dooley L, Lee NY, et al. Patterns of regional and distant metastasis in esthesioneuroblastoma. Laryngoscope 2016; 126:1556.</a></li><li><a class="nounderline abstract_t">De Virgilio A, Costantino A, Sebastiani D, et al. Elective neck irradiation in the management of esthesioneuroblastoma: a systematic review and meta-analysis. Rhinology 2021; 59:433.</a></li><li><a class="nounderline abstract_t">Jiang W, Mohamed AS, Fuller CD, et al. The role of elective nodal irradiation for esthesioneuroblastoma patients with clinically negative neck. Pract Radiat Oncol 2016; 6:241.</a></li><li><a class="nounderline abstract_t">Marinelli JP, Janus JR, Van Gompel JJ, et al. Esthesioneuroblastoma with distant metastases: Systematic review &amp; meta-analysis. Head Neck 2018; 40:2295.</a></li><li><a class="nounderline abstract_t">Brisson RJ, Quinn TJ, Deraniyagala RL. The role of chemotherapy in the management of olfactory neuroblastoma: A 40-year surveillance, epidemiology, and end results registry study. Health Sci Rep 2021; 4:e257.</a></li><li><a class="nounderline abstract_t">Resto VA, Eisele DW, Forastiere A, et al. Esthesioneuroblastoma: the Johns Hopkins experience. Head Neck 2000; 22:550.</a></li><li><a class="nounderline abstract_t">Weiden PL, Yarington CT Jr, Richardson RG. Olfactory neuroblastoma. Chemotherapy and radiotherapy for extensive disease. Arch Otolaryngol 1984; 110:759.</a></li><li><a class="nounderline abstract_t">Sheehan JM, Sheehan JP, Jane JA Sr, Polin RS. Chemotherapy for esthesioneuroblastomas. Neurosurg Clin N Am 2000; 11:693.</a></li><li><a class="nounderline abstract_t">Mishima Y, Nagasaki E, Terui Y, et al. Combination chemotherapy (cyclophosphamide, doxorubicin, and vincristine with continuous-infusion cisplatin and etoposide) and radiotherapy with stem cell support can be beneficial for adolescents and adults with estheisoneuroblastoma. Cancer 2004; 101:1437.</a></li><li><a class="nounderline abstract_t">Wade PM Jr, Smith RE, Johns ME. Response of esthesioneuroblastoma to chemotherapy. Report of five cases and review of the literature. Cancer 1984; 53:1036.</a></li><li><a class="nounderline abstract_t">McElroy EA Jr, Buckner JC, Lewis JE. Chemotherapy for advanced esthesioneuroblastoma: the Mayo Clinic experience. Neurosurgery 1998; 42:1023.</a></li><li><a class="nounderline abstract_t">Chamberlain MC. Treatment of intracranial metastatic esthesioneuroblastoma. Cancer 2002; 95:243.</a></li><li><a class="nounderline abstract_t">Heros DO, Hochberg FH. Treatment of esthesioneuroblastoma with chemotherapy: a report of two cases. J Neurooncol 1988; 6:141.</a></li><li><a class="nounderline abstract_t">Kim DW, Jo YH, Kim JH, et al. Neoadjuvant etoposide, ifosfamide, and cisplatin for the treatment of olfactory neuroblastoma. Cancer 2004; 101:2257.</a></li><li><a class="nounderline abstract_t">Kiyota N, Tahara M, Fujii S, et al. Nonplatinum-based chemotherapy with irinotecan plus docetaxel for advanced or metastatic olfactory neuroblastoma: a retrospective analysis of 12 cases. Cancer 2008; 112:885.</a></li><li><a class="nounderline abstract_t">Turano S, Mastroianni C, Manfredi C, et al. Advanced adult esthesioneuroblastoma successfully treated with cisplatin and etoposide alternated with doxorubicin, ifosfamide and vincristine. J Neurooncol 2010; 98:131.</a></li><li><a class="nounderline abstract_t">Wick W, Wick A, Küker W, et al. Intracranial metastatic esthesioneuroblastoma responsive to temozolomide. J Neurooncol 2004; 70:73.</a></li><li><a class="nounderline abstract_t">Preusser M, Hutterer M, Sohm M, et al. Disease stabilization of progressive olfactory neuroblastoma (esthesioneuroblastoma) under treatment with sunitinib mesylate. J Neurooncol 2010; 97:305.</a></li><li><a class="nounderline abstract_t">Mao L, Xia YP, Zhou YN, et al. Activation of sonic hedgehog signaling pathway in olfactory neuroblastoma. Oncology 2009; 77:231.</a></li><li><a class="nounderline abstract_t">London NR Jr, Rooper LM, Bishop JA, et al. Expression of Programmed Cell Death Ligand 1 and Associated Lymphocyte Infiltration in Olfactory Neuroblastoma. World Neurosurg 2020; 135:e187.</a></li><li><a class="nounderline abstract_t">Hasan OK, Ravi Kumar AS, Kong G, et al. Efficacy of Peptide Receptor Radionuclide Therapy for Esthesioneuroblastoma. J Nucl Med 2020; 61:1326.</a></li><li><a class="nounderline abstract_t">Schneider JR, Shatzkes DR, Scharf SC, et al. Neuroradiological and Neuropathological Changes After 177Lu-Octreotate Peptide Receptor Radionuclide Therapy of Refractory Esthesioneuroblastoma. Oper Neurosurg (Hagerstown) 2018; 15:100.</a></li><li><a class="nounderline abstract_t">Makis W, McCann K, McEwan AJ. Esthesioneuroblastoma (olfactory neuroblastoma) treated with 111In-octreotide and 177Lu-DOTATATE PRRT. Clin Nucl Med 2015; 40:317.</a></li><li><a class="nounderline abstract_t">Sabongi JG, Gonçalves MC, Alves CD, et al. Lutetium 177-DOTA-TATE therapy for esthesioneuroblastoma: A case report. Exp Ther Med 2016; 12:3078.</a></li><li><a class="nounderline abstract_t">Venkatramani R, Pan H, Furman WL, et al. Multimodality Treatment of Pediatric Esthesioneuroblastoma. Pediatr Blood Cancer 2016; 63:465.</a></li><li><a class="nounderline abstract_t">El Kababri M, Habrand JL, Valteau-Couanet D, et al. Esthesioneuroblastoma in children and adolescent: experience on 11 cases with literature review. J Pediatr Hematol Oncol 2014; 36:91.</a></li><li><a class="nounderline abstract_t">Safi C, Spielman D, Otten M, et al. Treatment Strategies and Outcomes of Pediatric Esthesioneuroblastoma: A Systematic Review. Front Oncol 2020; 10:1247.</a></li><li><a class="nounderline abstract_t">Yin Z, Wang Y, Wu Y, et al. Age distribution and age-related outcomes of olfactory neuroblastoma: a population-based analysis. Cancer Manag Res 2018; 10:1359.</a></li><li><a class="nounderline abstract_t">Zeng Q, Tian Y, He Y, et al. Long-Term Survival Outcomes and Treatment Experience of 64 Patients With Esthesioneuroblastoma. Front Oncol 2021; 11:624960.</a></li><li><a class="nounderline abstract_t">Goshtasbi K, Abiri A, Abouzari M, et al. Hyams grading as a predictor of metastasis and overall survival in esthesioneuroblastoma: a meta-analysis. Int Forum Allergy Rhinol 2019; 9:1054.</a></li><li><a class="nounderline abstract_t">McMillan RA, Van Gompel JJ, Link MJ, et al. Long-term oncologic outcomes in esthesioneuroblastoma: An institutional experience of 143 patients. Int Forum Allergy Rhinol 2022; 12:1457.</a></li><li><a class="nounderline abstract_t">Rimmer J, Lund VJ, Beale T, et al. Olfactory neuroblastoma: a 35-year experience and suggested follow-up protocol. Laryngoscope 2014; 124:1542.</a></li></ol></div><div id="topicVersionRevision">Topic 5183 Version 40.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="javascript:alert('بدون لینک');" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Neuroectodermal tumours. In: Pathology and Genetics of Head and Neck Tumours, Barnes L, Eveson JW, Reichart P, Sidransky D (Eds), IARC Press, Lyon, France 2005.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20596981" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Olfactory neuroblastoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30194694" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : A Population-Based Analysis of Nodal Metastases in Esthesioneuroblastomas of the Sinonasal Tract.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19721769" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Esthesioneuroblastoma: Results and Outcomes of a Single Institution's Experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18469486" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Two cases of ectopic adrenocorticotropic hormone syndrome with olfactory neuroblastoma and literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18575019" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Paraneoplastic refractory hypercalcemia due to advanced metastatic esthesioneuroblastoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24170477" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : A case and a series of published cases of esthesioneuroblastoma (ENB) in which long-standing paraneoplastic SIADH had preceded ENB diagnosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26199564" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Paraneoplastic syndromes in olfactory neuroblastoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1260676" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Olfactory neuroblastoma. A clinical analysis of 17 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8492845" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Esthesioneuroblastoma: prognosis and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29427378" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Dural recurrence among esthesioneuroblastoma patients presenting with intracranial extension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30210978" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Dural Invasion Predicts the Laterality and Development of Neck Metastases in Esthesioneuroblastoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17372086" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Esthesioneuroblastoma: a population-based analysis of survival and prognostic factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9252701" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Esthesioneuroblastoma: a general review of the cases published since the discovery of the tumour in 1924.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31930719" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Pattern of loco-regional relapses and treatment in pediatric esthesioneuroblastoma: The French very rare tumors group (Fracture) contribution.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28815831" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Prognostic significance of Kadish staging in esthesioneuroblastoma: An analysis of the National Cancer Database.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1495347" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Esthesioneuroblastoma: the UCLA experience 1970-1990.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32286935" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Comparing Kadish and Modified Dulguerov Staging Systems for Olfactory Neuroblastoma: An Individual Participant Data Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30466166" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Comparing Kadish, TNM, and the modified Dulguerov staging systems for esthesioneuroblastoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34980502" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Clinical outcomes, Kadish-INSICA staging and therapeutic targeting of somatostatin receptor 2 in olfactory neuroblastoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10542931" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Computed tomography and magnetic resonance imaging features of olfactory neuroblastoma: an analysis of 22 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8282874" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : MRI of esthesioneuroblastoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9673731" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Imaging of olfactory neuroblastoma--an analysis of 17 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21349970" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Patterns of regional spread for esthesioneuroblastoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22728262" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : The added value of 18F-FDG PET/CT for evaluation of patients with esthesioneuroblastoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24751700" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Long-term follow-up using 18F-FDG PET/CT for postoperative olfactory neuroblastoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16470879" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Clinical utility of somatostatin receptor scintigraphic imaging (octreoscan) in esthesioneuroblastoma: a case study and survey of somatostatin receptor subtype expression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29807052" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Frequent expression of somatostatin receptor 2a in olfactory neuroblastomas: a new and distinctive feature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33929681" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : SSTR2 Expression in Olfactory Neuroblastoma: Clinical and Therapeutic Implications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32796449" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : 68Ga-DOTATATE and 123I-mIBG as imaging biomarkers of disease localisation in metastatic neuroblastoma: implications for molecular radiotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33786927" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : The value of 68 Gallium-DOTATATE PET/CT in sinonasal neuroendocrine tumor management: A case series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33786927" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : The value of 68 Gallium-DOTATATE PET/CT in sinonasal neuroendocrine tumor management: A case series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11902539" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Esthesioneuroblastoma: a meta-analysis and review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33770323" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Consolidating the Hyams grading system in esthesioneuroblastoma - an individual participant data meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25685649" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Esthesioneuroblastoma: an update on the UCLA experience, 2002-2013.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8630875" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Olfactory neuroblastoma. An immunohistochemical, ultrastructural, and flow cytometric study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34401496" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : The genomics and epigenetics of olfactory neuroblastoma: A systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32558242" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Targeted 595-gene genomic profiling demonstrates low tumor mutational burden in olfactory neuroblastoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34064009" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Gene Expression Profiling of Olfactory Neuroblastoma Helps Identify Prognostic Pathways and Define Potentially Therapeutic Targets.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28495808" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Comprehensive Genomic Profiling of Esthesioneuroblastoma Reveals Additional Treatment Options.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28775129" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Comprehensive Molecular Profiling of Olfactory Neuroblastoma Identifies Potentially Targetable FGFR3 Amplifications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29730775" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : DNA methylation-based reclassification of olfactory neuroblastoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29427030" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Sinonasal Neuroendocrine Neoplasms: Current Challenges and Advances in Diagnosis and Treatment, with a Focus on Olfactory Neuroblastoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16119901" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Misdiagnosis of olfactory neuroblastoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22020045" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Calretinin staining facilitates differentiation of olfactory neuroblastoma from other small round blue cell tumors in the sinonasal tract.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22020045" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Calretinin staining facilitates differentiation of olfactory neuroblastoma from other small round blue cell tumors in the sinonasal tract.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2430477" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Sinonasal undifferentiated carcinoma. An aggressive neoplasm derived from schneiderian epithelium and distinct from olfactory neuroblastoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2692105" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : "Undifferentiated" neoplasms of the sinonasal region: differential diagnosis based on clinical, light microscopic, immunohistochemical, and ultrastructural features.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31186531" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : DNA methylation-based classification of sinonasal undifferentiated carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35420559" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Sinonasal Tumors With Neuroepithelial Differentiation (Olfactory Carcinoma): Delineation of Their Pathologic and Clinical Features With Insights into Their Relationship to Olfactory Neuroblastoma and Sinonasal Carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19240832" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Esthesioneuroblastoma: the massachusetts eye and ear infirmary and massachusetts general hospital experience with craniofacial resection, proton beam radiation, and chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11224781" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Esthesioneuroblastoma: the University of Iowa experience 1978-1998.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27256979" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Genetic and molecular alterations in olfactory neuroblastoma: implications for pathogenesis, prognosis and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29324814" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Comprehensive molecular profiling of advanced/metastatic olfactory neuroblastomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31329374" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : ICAR: endoscopic skull-base surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26514662" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Comparison of outcomes for open versus endoscopic approaches for olfactory neuroblastoma: A systematic review and individual participant data meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3724324" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Esthesioneuroblastoma: the University of Virginia experience 1960-1985.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15806328" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Combined endoscopic surgery and radiosurgery as treatment modality for olfactory neuroblastoma (esthesioneuroblastoma).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19379620" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Endoscopic endonasal resection of esthesioneuroblastoma: a multicenter study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19434247" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Endoscopic versus traditional craniofacial resection for patients with sinonasal tumors involving the anterior skull base.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18588765" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Endoscopic surgery for malignant tumors of the sinonasal tract and adjacent skull base: a 10-year experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30074458" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Endonasal endoscopic resection of olfactory neuroblastoma: an 11-year experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29356209" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Multicenter assessment of exclusive endoscopic endonasal approach for the treatment of 53 olfactory neuroblastomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28595773" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Endoscopic endonasal management of esthesioneuroblastoma: A retrospective multicenter study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35619935" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Exclusively endoscopic surgical resection of esthesioneuroblastoma: A systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32627574" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Comparison of Open and Endoscopic Approaches in the Resection of Esthesioneuroblastoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19444891" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Treatment of esthesioneuroblastoma: a 16-year meta-analysis of 361 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29226334" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Early Stage olfactory neuroblastoma and the impact of resecting dura and olfactory bulb.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29868325" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Esthesioneuroblastoma and Olfactory Preservation: Is it Reasonable to Attempt Smell Preservation?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19205593" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Radiotherapy alone for local tumour control in esthesioneuroblastoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18755554" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Intensity-modulated radiotherapy for sinonasal tumors: Ghent University Hospital update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27084655" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Outcomes of Sinonasal Cancer Treated With Proton Therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28062086" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Proton beam therapy for olfactory neuroblastoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28062086" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Proton beam therapy for olfactory neuroblastoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25820437" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Proton therapy for pediatric and adolescent esthesioneuroblastoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24980873" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Charged particle therapy versus photon therapy for paranasal sinus and nasal cavity malignant diseases: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24083125" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Long-term outcome of esthesioneuroblastoma: hyams grade predicts patient survival.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30862589" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Esthesioneuroblastoma: A Comprehensive Review of Diagnosis, Management, and Current Treatment Options.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31423376" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Esthesioneuroblastoma: Summary of Single-center Experiences with Focus on Adjuvant Therapy and Overall Survival.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25356502" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Importance of tumor grade in esthesioneuroblastoma survival: a population-based analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34272876" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Long-Term Outcomes of Olfactory Neuroblastoma: MD Anderson Cancer Center Experience and Review of the Literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15654688" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Olfactory neuroblastoma: the 22-year experience at one comprehensive cancer center.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18798301" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Esthesioneuroblastoma: The Princess Margaret Hospital experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12616204" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Olfactory neuroblastoma: past, present, and future?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12737303" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Esthesioneuroblastoma: a Danish demographic study of 40 patients registered between 1978 and 2000.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8244813" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Esthesioneuroblastoma: the role of adjuvant radiation therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20231062" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Outcome and prognostic factors in olfactory neuroblastoma: a rare cancer network study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23780581" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Optimization of long-term outcomes for patients with esthesioneuroblastoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31842117" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Chemotherapy in Esthesioneuroblastoma/Olfactory Neuroblastoma: An Analysis of the Surveillance Epidemiology and End Results (SEER) 1973-2015 Database.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12173330" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Neuroendocrine tumors of the sinonasal tract. Results of a prospective study incorporating chemotherapy, surgery, and combined proton-photon radiotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12707712" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Multimodality therapy including radiotherapy and chemotherapy improves event-free survival in stage C esthesioneuroblastoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8491582" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Olfactory neuroblastoma: the results of modern treatment approaches at the University of Michigan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16490869" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Esthesioneuroblastoma: continued follow-up of a single institution's experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12514401" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Esthesioneuroblastoma: the Northwestern University experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29061289" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Importance of neoadjuvant chemotherapy in olfactory neuroblastoma treatment: Series report and literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28561956" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Outcomes for olfactory neuroblastoma treated with induction chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30536472" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Utility of adjuvant chemotherapy in patients receiving surgery and adjuvant radiotherapy for primary treatment of esthesioneuroblastoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37164774" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : The SINTART 1 study. A phase II non-randomised controlled trial of induction chemotherapy, surgery, photon-, proton- and carbon ion-based radiotherapy integration in patients with locally advanced resectable sinonasal tumours.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26671900" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Olfactory Neuroblastoma: Fate of the Neck--A Long-term Multicenter Retrospective Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21676553" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Esthesioneuroblastoma: is there a need for elective neck treatment?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28180046" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Risk of Delayed Lymph Node Metastasis in Clinically N0 Esthesioneuroblastoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26865537" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Patterns of regional and distant metastasis in esthesioneuroblastoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34254061" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Elective neck irradiation in the management of esthesioneuroblastoma: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26979544" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : The role of elective nodal irradiation for esthesioneuroblastoma patients with clinically negative neck.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29756250" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Esthesioneuroblastoma with distant metastases: Systematic review&amp;meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33969231" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : The role of chemotherapy in the management of olfactory neuroblastoma: A 40-year surveillance, epidemiology, and end results registry study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10941155" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Esthesioneuroblastoma: the Johns Hopkins experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6541469" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Olfactory neuroblastoma. Chemotherapy and radiotherapy for extensive disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11082179" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Chemotherapy for esthesioneuroblastomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15368332" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Combination chemotherapy (cyclophosphamide, doxorubicin, and vincristine with continuous-infusion cisplatin and etoposide) and radiotherapy with stem cell support can be beneficial for adolescents and adults with estheisoneuroblastoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6362834" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Response of esthesioneuroblastoma to chemotherapy. Report of five cases and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9588546" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Chemotherapy for advanced esthesioneuroblastoma: the Mayo Clinic experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12124822" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Treatment of intracranial metastatic esthesioneuroblastoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3225636" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Treatment of esthesioneuroblastoma with chemotherapy: a report of two cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15484215" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Neoadjuvant etoposide, ifosfamide, and cisplatin for the treatment of olfactory neuroblastoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18189294" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Nonplatinum-based chemotherapy with irinotecan plus docetaxel for advanced or metastatic olfactory neuroblastoma: a retrospective analysis of 12 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19924514" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Advanced adult esthesioneuroblastoma successfully treated with cisplatin and etoposide alternated with doxorubicin, ifosfamide and vincristine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15527110" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Intracranial metastatic esthesioneuroblastoma responsive to temozolomide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19820899" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Disease stabilization of progressive olfactory neuroblastoma (esthesioneuroblastoma) under treatment with sunitinib mesylate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19738389" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Activation of sonic hedgehog signaling pathway in olfactory neuroblastoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31785431" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Expression of Programmed Cell Death Ligand 1 and Associated Lymphocyte Infiltration in Olfactory Neuroblastoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32005769" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : Efficacy of Peptide Receptor Radionuclide Therapy for Esthesioneuroblastoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29554305" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : Neuroradiological and Neuropathological Changes After 177Lu-Octreotate Peptide Receptor Radionuclide Therapy of Refractory Esthesioneuroblastoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25674857" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : Esthesioneuroblastoma (olfactory neuroblastoma) treated with 111In-octreotide and 177Lu-DOTATATE PRRT.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27882120" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : Lutetium 177-DOTA-TATE therapy for esthesioneuroblastoma: A case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26514449" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : Multimodality Treatment of Pediatric Esthesioneuroblastoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24390450" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : Esthesioneuroblastoma in children and adolescent: experience on 11 cases with literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32793498" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : Treatment Strategies and Outcomes of Pediatric Esthesioneuroblastoma: A Systematic Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29881306" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : Age distribution and age-related outcomes of olfactory neuroblastoma: a population-based analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33747939" id="rid129" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>130 : Long-Term Survival Outcomes and Treatment Experience of 64 Patients With Esthesioneuroblastoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31251848" id="rid130" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>131 : Hyams grading as a predictor of metastasis and overall survival in esthesioneuroblastoma: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35385606" id="rid131" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>132 : Long-term oncologic outcomes in esthesioneuroblastoma: An institutional experience of 143 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24347437" id="rid132" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>133 : Olfactory neuroblastoma: a 35-year experience and suggested follow-up protocol.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
